Study of a New Thermo Stable Formulation of Epoprostenol Sodium to Treat Pulmonary Arterial Hypertension (PAH)
Status:
Completed
Trial end date:
2012-11-08
Target enrollment:
Participant gender:
Summary
The purpose of this multicentre, open label, single-arm study in approximately 20 adult
patients is to evaluate the Impact on lifestyle of a new thermo stable formulation of
epoprostenol sodium in subjects with Pulmonary Arterial Hypertension (PAH).